Title: Consolidative Chemotherapy after Definitive Concurrent Chemoradiotherapy for
Esophageal Squamous Cell Carcinoma Patients: a Population Based Cohort Study
Version: 1 Date: 28 May 2022
Reviewer's report:
the study of consolidative chemotherapy after concurrent chemoradiotharypy in esophageal
squamous cell carcinoma is very valuable.  As we know that the number of chemotherapy
cycles concurrent with radiation has the relationship with the chemotherapy regiments. It is
recommended to add 2-3 cycles after the concurrent chemoradiotherapy with oxaplatin/cisplatin
plus 5-Fu and no addition with taxane in clinical guidelines. Dose the difference in this study
come from the different cycles of chemotherapy or the different regiments of chemotherapy? by
the way, the discussion has no content.
Title: Consolidative Chemotherapy after Definitive Concurrent Chemoradiotherapy for
Esophageal Squamous Cell Carcinoma Patients: a Population Based Cohort Study
Version: 1 Date: 28 May 2022
Reviewer's report:
the study of consolidative chemotherapy after concurrent chemoradiotharypy in esophageal
squamous cell carcinoma is very valuable.  As we know that the number of chemotherapy
cycles concurrent with radiation has the relationship with the chemotherapy regiments. It is
recommended to add 2-3 cycles after the concurrent chemoradiotherapy with oxaplatin/cisplatin
plus 5-Fu and no addition with taxane in clinical guidelines. Dose the difference in this study
come from the different cycles of chemotherapy or the different regiments of chemotherapy? by
the way, the discussion has no content.
Please review this paper.
user
Title: Consolidative Chemotherapy after Definitive Concurrent Chemoradiotherapy for
Esophageal Squamous Cell Carcinoma Patients: a Population Based Cohort Study
Version: 1 Date: 28 May 2022
Reviewer's report:
the study of consolidative chemotherapy after concurrent chemoradiotharypy in esophageal
squamous cell carcinoma is very valuable.  As we know that the number of chemotherapy
cycles concurrent with radiation has the relationship with the chemotherapy regiments. It is
recommended to add 2-3 cycles after the concurrent chemoradiotherapy with oxaplatin/cisplatin
plus 5-Fu and no addition with taxane in clinical guidelines. Dose the difference in this study
come from the different cycles of chemotherapy or the different regiments of chemotherapy? by
the way, the discussion has no content.
assistant